|
시장보고서
상품코드
2039090
신경섬유종증 치료제 시장 : 질환별, 유통 채널별, 지역별Neurofibromatosis Treatment Drugs Market, By Disease Type, By Distribution Channel, By Geography |
||||||
가격
※ 부가세 별도
한글목차
영문목차
※ 본 상품은 영문 자료로 한글과 영문 목차에 불일치하는 내용이 있을 경우 영문을 우선합니다. 정확한 검토를 위해 영문 목차를 참고해주시기 바랍니다.
신경섬유종증 치료제 시장은 2026년에 207억 8,500만 달러로 추정되며, 2033년까지 490억 8,500만 달러에 달할 것으로 예상됩니다. 2026년부터 2033년까지 CAGR 13.4%로 성장할 것으로 전망됩니다.
| 보고서 범위 | 보고서 상세 | ||
|---|---|---|---|
| 기준 연도: | 2025년 | 2026년 시장 규모: | 207억 8,500만 달러 |
| 과거 데이터 기간: | 2020-2024년 | 예측 기간: | 2026-2033년 |
| 2026년부터 2033년까지 예측 기간 CAGR: | 13.40% | 2033년 시장 규모 예측: | 490억 8,500만 달러 |
신경섬유종증은 신경계의 유전성 질환입니다. 주로 신경세포의 성장에 영향을 미칩니다. 신경 위에 종양이 생기는 것이 특징입니다. 신경섬유종증은 주로 소아에게 발병하는 유전성 질환으로 여겨지지만, 유전자의 돌연변이(변화)에 의해 발병하기도 합니다. 보통 신경섬유종증의 종양은 양성이지만 때로는 악성으로 변할 수도 있습니다. 신경섬유종증에는 1형(NF1), 2형(NF2), 슈반노마병의 세 가지 유형이 있습니다. 이 세 가지 유형은 모두 다양한 증상을 나타냅니다.
시장 역학
제약회사와 생명공학 기업들이 신경섬유종증 치료제 연구개발에 집중하고 있는 것은 예측 기간 동안 신경섬유종증 치료제 시장의 성장을 견인할 것으로 예상됩니다. 예를 들어, 2020년 7월 8일 노벨파마는 제1형 신경섬유종증 환자를 대상으로 NPC-12G 겔의 장기 치료의 안전성과 유효성을 평가하기 위한 3상 임상시험을 시작했습니다. 본 시험은 2022년 4월 30일에 완료될 예정입니다.
본 조사의 주요 특징
- 이 보고서는 다양한 부문의 잠재적 수익 창출 기회를 밝히고, 이 시장에서 매력적인 투자 제안 매트릭스를 설명합니다.
- 또한 시장 촉진요인, 억제요인, 기회, 신약 출시 및 승인, 시장 동향, 지역별 전망, 주요 기업의 경쟁 전략에 대한 중요한 인사이트도 제공합니다.
- 이 조사는 다음과 같은 매개 변수를 기반으로 세계 신경섬유종증 치료제 시장의 주요 기업 프로파일을 작성했습니다. 구체적으로 기업 개요, 재무실적, 의약품 포트폴리오, 시장에서의 존재감, 유통 전략, 주요 발전, 전략 및 향후 계획 등입니다.
- 이번 조사에 포함된 주요 기업으로는 아스트라제네카(AstraZeneca)가 있습니다.
- 이 보고서의 내용을 통해 기업의 마케팅 담당자와 경영진은 향후 의약품 출시, 약물군 업그레이드, 시장 확대 및 마케팅 전략에 대한 정보에 입각한 의사결정을 내릴 수 있을 것입니다.
- 이 "세계 신경섬유종증 치료제 시장 보고서"는 투자자, 공급업체, 제약회사, 유통업체, 신규 진입자, 금융 분석가 등 업계의 다양한 이해관계자를 대상으로 합니다.
- 이해관계자들은 세계 신경섬유종증 치료제제 시장 분석에 사용되는 다양한 전략 매트릭스를 통해 의사결정을 쉽게 내릴 수 있을 것입니다.
목차
제1장 조사 목적과 가정
제2장 시장 범위
제3장 시장 역학, 규제 및 동향 분석
제4장 세계의 신경섬유종증 치료제 시장 : 질환 유형별, 2021-2033년
제5장 세계의 신경섬유종증 치료제 시장 : 유통 채널별, 2021-2033년
제6장 세계의 신경섬유종증 치료제 시장 : 지역별, 2021-2033년
제7장 경쟁 구도
제8장 애널리스트의 추천
제9장 참고문헌 및 조사 방법
KSM 26.06.04Neurofibromatosis Treatment Drugs Market is estimated to be valued at USD 20,785 Mn in 2026 and is expected to reach USD 49,085 Mn by 2033, growing at a compound annual growth rate (CAGR) of 13.4% from 2026 to 2033.
| Report Coverage | Report Details | ||
|---|---|---|---|
| Base Year: | 2025 | Market Size in 2026: | USD 20,785 Mn |
| Historical Data for: | 2020 To 2024 | Forecast Period: | 2026 To 2033 |
| Forecast Period 2026 to 2033 CAGR: | 13.40% | 2033 Value Projection: | USD 49,085 Mn |
Neurofibromatosis is a genetic disorder of the nervous system. It mainly affects growth of nerve cells. It is characterized by the growth of tumors on nerves. Neurofibromatosis is considered as a hereditary disease which mainly occurs in children or it can happen due to mutation (change) of genes. Usually the Neurofibromatosis tumors are benign, but sometimes they can become cancerous. There are three types of neurofibromatosis: Type 1 (NF1), Type 2 (NF2), and Schwannomatosis. All three types show varied symptoms.
Market Dynamics
The increasing focus of pharma and biotech companies on the research and development of novel treatment drugs for neurofibromatosis is expected to drive the neurofibromatosis treatment drugs market growth during the forecast period. For instance, on July 8, 2020, Nobelpharma initiated phase 3 clinical trial study to evaluate the safety and efficacy of long-term treatment with NPC-12G gel for patients with neurofibromatosis type I. The study is estimated to complete in April 30, 2022.
Key features of the study
- It elucidates potential revenue opportunities across different segments and explains attractive investment proposition matrices for this market
- This study also provides key insights about market drivers, restraints, opportunities, new drug launches or approval, market trends, regional outlook, and competitive strategies adopted by key players
- It profiles key players in the global neurofibromatosis treatment drugs market based on the following parameters - company overview, financial performance, drugs portfolio, market presence, distribution strategies, key developments, strategies, and future plans
- Key company covered as a part of this study includes AstraZeneca
- Insights from this report would allow marketers and the management authorities of the companies to make informed decisions regarding their future drug launches, drug class up-gradation, market expansion, and marketing tactics
- The global neurofibromatosis treatment drugs market report caters to various stakeholders in this industry including investors, suppliers, drugs manufacturers, distributors, new entrants, and financial analysts
- Stakeholders would have ease in decision-making through various strategy matrices used in analyzing the global neurofibromatosis treatment drugs market.
Neurofibromatosis Treatment Drugs Market Segmentation
- By Disease Type (Revenue, USD Mn, 2026-2033)
- Neurofibromatosis 1 (NF1)
- Neurofibromatosis 2 (NF2)
- Schwannomatosis
- By Distribution Channel (Revenue, USD Mn, 2026-2033)
- Hospital Pharmacies
- Retail Pharmacies
- Online Pharmacies
- By Region (Revenue, USD Mn, 2026-2033)
- North America
- U.S.
- Canada
- Latin America
- Brazil
- Mexico
- Argentina
- Rest of Latin America
- Europe
- Germany
- U.K.
- France
- Italy
- Spain
- Russia
- Rest of Europe
- Asia Pacific
- China
- India
- Japan
- Australia
- South Korea
- ASEAN
- Rest of Asia Pacific
- Middle East
- GCC
- Israel
- Rest of Middle East
- Africa
- South Africa
- Central Africa
- North Africa
- Key Players
- AstraZeneca
- SpringWorks Therapeutics
- Novartis
- Pfizer
- Takeda Pharmaceutical
- Roche
- Healx
- NFlection Therapeutics
- Fosun Pharmaceutical
- Recursion Pharmaceuticals
Table of Contents
1. Research Objectives and Assumptions
- Research Objectives
- Assumptions
- Abbreviations
2. Market Purview
- Report Description
- Market Definition and Scope
- Executive Summary
- Market Snippet, By Disease Type
- Market Snippet, By Distribution Channel
- Market Snippet, By Region
- Coherent Opportunity Map (COM)
3. Market Dynamics, Regulations, and Trends Analysis
- Market Dynamics
- Drivers
- Restraints
- Impact Analysis
- Market Opportunities
- Collaborations and Acquisition
- Regulatory Scenario
4. Global Neurofibromatosis Treatment Drugs Market, By Disease Type, 2021-2033 (USD Mn)
- Introduction
- Market Share Analysis, 2026, and 2033 (%)
- Y-o-Y Growth Analysis, 2022 - 2033
- Segment Trends
- Neurofibromatosis 1 (NF1)
- Y-o-Y Growth Analysis, 2021 - 2033
- Segment Trends
- Neurofibromatosis 2 (NF2)
- Y-o-Y Growth Analysis, 2021 - 2033
- Segment Trends
- Schwannomatosis
- Y-o-Y Growth Analysis, 2021 - 2033
- Segment Trends
5. Global Neurofibromatosis Treatment Drugs Market, By Distribution Channel, 2021-2033 (USD Mn)
- Introduction
- Market Share Analysis, 2026 and 2033 (%)
- Y-o-Y Growth Analysis, 2022- 2033
- Segment Trends
- Hospital Pharmacies
- Y-o-Y Growth Analysis, 2021 - 2033
- Segment Trends
- Retail Pharmacies
- Y-o-Y Growth Analysis, 2021 - 2033
- Segment Trends
- Online Pharmacies
- Y-o-Y Growth Analysis, 2021 - 2033
- Segment Trends
6. Global Neurofibromatosis Treatment Drugs Market, By Region, 2021-2033 (USD Mn)
- Introduction
- Market Share Analysis, By Region, 2026, and 2033 (%)
- Y-o-Y Growth Analysis, For Region, 2022 - 2033
- North America
- Y-o-Y Growth Analysis, For Country, 2021 - 2033
- Market Size and Forecast, By Disease Type, 2026- 2033, (USD Mn)
- Market Size and Forecast, By Distribution Channel, 2026- 2033, (USD Mn)
- Market Size and Forecast, By Country, 2026- 2033, (USD Mn)
- U.S.
- Canada
- Latin America
- Y-o-Y Growth Analysis, For Country, 2021 - 2033
- Market Size and Forecast, By Disease Type, 2026- 2033, (USD Mn)
- Market Size and Forecast, By Distribution Channel, 2026- 2033, (USD Mn)
- Market Size and Forecast, By Country, 2026- 2033, (USD Mn)
- Brazil
- Mexico
- Argentina
- Rest of Latin America
- Europe
- Y-o-Y Growth Analysis, For Country, 2021 - 2033
- Market Size and Forecast, By Disease Type, 2026- 2033, (USD Mn)
- Market Size and Forecast, By Distribution Channel, 2026- 2033, (USD Mn)
- Market Size and Forecast, By Country, 2026- 2033, (USD Mn)
- Germany
- U.K.
- France
- Italy
- Spain
- Russia
- Rest of Europe
- Asia Pacific
- Y-o-Y Growth Analysis, For Country, 2021 - 2033
- Market Size and Forecast, By Disease Type, 2026- 2033, (USD Mn)
- Market Size and Forecast, By Distribution Channel, 2026- 2033, (USD Mn)
- Market Size and Forecast, By Country, 2026- 2033, (USD Mn)
- China
- India
- Japan
- Australia
- South Korea
- ASEAN
- Rest of Asia Pacific
- Middle East
- Y-o-Y Growth Analysis, For Country, 2021 - 2033
- Market Size and Forecast, By Disease Type, 2026- 2033, (USD Mn)
- Market Size and Forecast, By Distribution Channel, 2026- 2033, (USD Mn)
- Market Size and Forecast, By Country, 2026- 2033, (USD Mn)
- GCC
- Israel
- Rest of Middle East
- Africa
- Y-o-Y Growth Analysis, For Country, 2021 - 2033
- Market Size and Forecast, By Disease Type, 2026- 2033, (USD Mn)
- Market Size and Forecast, By Distribution Channel, 2026- 2033, (USD Mn)
- Market Size and Forecast, By Country, 2026- 2033, (USD Mn)
- South Africa
- Central Africa
- North Africa
7. Competitive Landscape
- Company Profiles
- AstraZeneca Plc
- Company Overview
- Disease Type Portfolio
- Financial Overview
- Key Highlights
- Market Strategies
- SpringWorks Therapeutics
- Company Overview
- Disease Type Portfolio
- Financial Overview
- Key Highlights
- Market Strategies
- Novartis
- Company Overview
- Disease Type Portfolio
- Financial Overview
- Key Highlights
- Market Strategies
- Pfizer
- Company Overview
- Disease Type Portfolio
- Financial Overview
- Key Highlights
- Market Strategies
- Takeda Pharmaceutical
- Company Overview
- Disease Type Portfolio
- Financial Overview
- Key Highlights
- Market Strategies
- Roche
- Company Overview
- Disease Type Portfolio
- Financial Overview
- Key Highlights
- Market Strategies
- Healx
- Company Overview
- Disease Type Portfolio
- Financial Overview
- Key Highlights
- Market Strategies
- NFlection Therapeutics
- Company Overview
- Disease Type Portfolio
- Financial Overview
- Key Highlights
- Market Strategies
- Fosun Pharmaceutical
- Company Overview
- Disease Type Portfolio
- Financial Overview
- Key Highlights
- Market Strategies
- Recursion Pharmaceuticals
- Company Overview
- Disease Type Portfolio
- Financial Overview
- Key Highlights
- Market Strategies
- AstraZeneca Plc
8. Analyst Recommendations
- Wheel of Fortune
- Analyst View
- Coherent Opportunity Map
9. References and Research Methodology
- References
- Research Methodology
- About us
